H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient DOI Creative Commons
Tamara Boschert, Kristina Kromer, Taga Lerner

и другие.

Science Advances, Год журнала: 2024, Номер 10(5)

Опубликована: Фев. 2, 2024

H3K27M, a driver mutation with T and B cell neoepitope characteristics, defines an aggressive subtype of diffuse glioma poor survival. We functionally dissect the immune response one patient treated H3K27M peptide vaccine who subsequently entered complete remission. The robustly expanded class II human leukocyte antigen (HLA)–restricted peripheral H3K27M-specific cells. Using functional assays, we characterized 34 clonally unique H3K27M-reactive receptors identified critical, conserved motifs in their complementarity-determining region 3 regions. detailed HLA mapping, further demonstrate that diverse HLA-DQ HLA-DR alleles present immunogenic epitopes. Furthermore, profiled from activated cells cerebrospinal fluid. Our results uncover breadth adaptive against shared clonal neoantigen across multiple allelotypes support use II–restricted vaccines to stimulate tumor-specific harboring therapeutic potential.

Язык: Английский

Neoantigens: promising targets for cancer therapy DOI Creative Commons
Na Xie, Guobo Shen, Wei Gao

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2023, Номер 8(1)

Опубликована: Янв. 6, 2023

Abstract Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy antibody-based therapies, especially for solid tumors. Neoantigens are newly formed antigens generated by cells as a result various tumor-specific alterations, such genomic mutation, dysregulated RNA splicing, disordered post-translational modification, integrated viral open reading frames. recognized non-self trigger an immune response that is not subject to central peripheral tolerance. The quick identification prediction neoantigens been made possible advanced next-generation sequencing bioinformatic technologies. Compared tumor-associated antigens, highly immunogenic provide emerging targets personalized serve prospective predictors survival prognosis checkpoint blockade responses. therapies will be aided understanding mechanism underlying neoantigen-induced anti-tumor streamlining process neoantigen-based immunotherapies. This review provides overview on characterization outlines clinical applications immunotherapeutic strategies based neoantigens. We also explore their current status, inherent challenges, translation potential.

Язык: Английский

Процитировано

496

Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions DOI Creative Commons
Daniel Butler, Christopher Mozsary, Cem Meydan

и другие.

Nature Communications, Год журнала: 2021, Номер 12(1)

Опубликована: Март 12, 2021

Abstract In less than nine months, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) killed over a million people, including >25,000 in New York City (NYC) alone. The COVID-19 pandemic caused by SARS-CoV-2 highlights clinical needs to detect infection, track strain evolution, and identify biomarkers of disease course. To address these challenges, we designed fast (30-minute) colorimetric test (LAMP) for infection from naso/oropharyngeal swabs large-scale shotgun metatranscriptomics platform (total-RNA-seq) host, viral, microbial profiling. We applied methods specimens gathered 669 patients during first two months outbreak, yielding broad molecular portrait emerging disease. find significant enrichment NYC-distinctive clade virus (20C), as well host responses interferon, ACE, hematological, olfaction pathways. addition, use 50,821 patient records that renin–angiotensin–aldosterone system inhibitors have protective effect severe outcomes, unlike similar drugs. Finally, spatial transcriptomic data autopsy tissues reveal distinct ACE2 expression loci, with macrophage neutrophil infiltration lungs. These findings can inform public health may help develop drive diagnostic, prevention, treatment strategies.

Язык: Английский

Процитировано

175

Next-generation computational tools for interrogating cancer immunity DOI
Francesca Finotello, Dietmar Rieder, Hubert Hackl

и другие.

Nature Reviews Genetics, Год журнала: 2019, Номер 20(12), С. 724 - 746

Опубликована: Сен. 12, 2019

Язык: Английский

Процитировано

149

Challenges in neoantigen-directed therapeutics DOI Creative Commons
Lien Lybaert, Steve Lefever, Bruno Fant

и другие.

Cancer Cell, Год журнала: 2022, Номер 41(1), С. 15 - 40

Опубликована: Ноя. 10, 2022

Язык: Английский

Процитировано

81

LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity DOI
Lawrence P. Andrews, Samuel C. Butler, Jian Cui

и другие.

Cell, Год журнала: 2024, Номер 187(16), С. 4355 - 4372.e22

Опубликована: Авг. 1, 2024

Язык: Английский

Процитировано

73

The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer DOI Creative Commons

Anne I. Kraemer,

Chloé Chong,

Florian Huber

и другие.

Nature Cancer, Год журнала: 2023, Номер 4(5), С. 608 - 628

Опубликована: Май 1, 2023

Abstract One key barrier to improving efficacy of personalized cancer immunotherapies that are dependent on the tumor antigenic landscape remains patient stratification. Although patients with CD3 + CD8 T cell-inflamed tumors typically show better response immune checkpoint inhibitors, it is still unknown whether immunopeptidome repertoire presented in highly inflamed and noninflamed substantially different. We surveyed 61 regions adjacent nonmalignant lung tissues from 8 performed deep antigen discovery combining immunopeptidomics, genomics, bulk spatial transcriptomics, explored heterogeneous expression presentation (neo)antigens. In present study, we associated diverse cell populations found a relatively higher frequency predicted neoantigens located within HLA-I hotspots cell-excluded tumors. such recognition, supporting their involvement editing. This could have implications for choice combination therapies tailored patient’s mutanome microenvironment.

Язык: Английский

Процитировано

52

Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy DOI
Guangyuan Li, Shweta Mahajan, Siyuan Ma

и другие.

Science Translational Medicine, Год журнала: 2024, Номер 16(730)

Опубликована: Янв. 17, 2024

Immunotherapy has emerged as a crucial strategy to combat cancer by “reprogramming” patient’s own immune system. Although immunotherapy is typically reserved for patients with high mutational burden, neoantigens produced from posttranscriptional regulation may provide an untapped reservoir of common immunogenic targets new targeted therapies. To comprehensively define tumor-specific and likely patient RNA-Seq, we developed Splicing Neo Antigen Finder (SNAF), easy-to-use open-source computational workflow predict splicing-derived MHC-bound peptides (T cell antigen) unannotated transmembrane proteins altered extracellular epitopes (B antigen). This uses highly accurate deep learning immunogenicity prediction (DeepImmuno) in conjunction algorithms rank the tumor specificity (BayesTS) regulators mis-splicing (RNA-SPRINT). T antigens SNAF were frequently evidenced HLA-presented mass spectrometry (MS) response melanoma. neoantigen burden was attributed coordinated splicing factor dysregulation. Shared found up 90% melanoma, correlated overall survival multiple cohorts, induced reactivity, characterized distinct cells origin amino acid preferences. In addition neoantigens, our B focused pipeline (SNAF-B) identified class neoepitopes, which termed ExNeoEpitopes. ExNeoEpitope full-length mRNA predictions specific validated using long-read isoform sequencing vitro localization assays. Therefore, systematic identification revealed potential shared therapy heterogeneous cancers.

Язык: Английский

Процитировано

33

Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy DOI Creative Commons
Chin Leng Tan, Katharina A.M. Lindner, Tamara Boschert

и другие.

Nature Biotechnology, Год журнала: 2024, Номер 43(1), С. 134 - 142

Опубликована: Март 7, 2024

The identification of patient-derived, tumor-reactive T cell receptors (TCRs) as a basis for personalized transgenic therapies remains time- and cost-intensive endeavor. Current approaches to identify TCRs analyze tumor mutations predict activating (neo)antigens use these either enrich infiltrating lymphocyte (TIL) cultures or validate individual autologous therapies. Here we combined high-throughput TCR cloning reactivity validation train predicTCR, machine learning classifier that identifies TILs in an antigen-agnostic manner based on single-TIL RNA sequencing. PredicTCR from diverse cancers better than previous gene set enrichment-based approaches, increasing specificity sensitivity (geometric mean) 0.38 0.74. By predicting matter days, clonotypes can be prioritized accelerate the manufacture

Язык: Английский

Процитировано

18

Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group DOI Creative Commons
Leticia De Mattos‐Arruda, Miguél Vázquez, Francesca Finotello

и другие.

Annals of Oncology, Год журнала: 2020, Номер 31(8), С. 978 - 990

Опубликована: Июнь 28, 2020

Язык: Английский

Процитировано

121

Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01 DOI Creative Commons
January Weiner, Phillip Suwalski, Manuel Holtgrewe

и другие.

EClinicalMedicine, Год журнала: 2021, Номер 40, С. 101099 - 101099

Опубликована: Сен. 2, 2021

BackgroundSince the beginning of coronavirus disease 2019 (COVID-19) pandemic, there has been increasing urgency to identify pathophysiological characteristics leading severe clinical course in patients infected with acute respiratory syndrome 2 (SARS-CoV-2). Human leukocyte antigen alleles (HLA) have suggested as potential genetic host factors that affect individual immune response SARS-CoV-2. We sought evaluate this hypothesis by conducting a multicenter study using HLA sequencing.MethodsWe analyzed association between COVID-19 severity and HLAs 435 individuals from Germany (n = 135), Spain 133), Switzerland 20) United States 147), who had enrolled March 2020 August 2020. This included older than 18 years, diagnosed representing full spectrum disease. Finally, we tested our results meta-analysing data prior genome-wide studies (GWAS).FindingsWe describe HLA-C*04:01 COVID-19. Carriers twice risk intubation when SARS-CoV-2 (risk ratio 1.5 [95% CI 1.1–2.1], odds 3.5 1.9–6.6], adjusted p-value 0.0074). These findings are based on four countries corroborated independent GWAS. Our biologically plausible, fewer predicted bindings sites for relevant peptides compared other alleles.InterpretationHLA-C*04:01 carrier state is associated suggest class I role defense against SARS-CoV-2.FundingFunded Roche Sequencing Solutions, Inc.

Язык: Английский

Процитировано

91